Sunshine Heart Inc (NASDAQ:CHFS) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Brokers have set a 1-year consensus price objective of $15.00 for the company, according to Zacks. Zacks has also assigned Sunshine Heart an industry rank of 158 out of 265 based on the ratings given to its competitors.

A number of research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Sunshine Heart from a “buy” rating to a “hold” rating in a report on Thursday. ValuEngine upgraded shares of Sunshine Heart from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 31st.

Shares of Sunshine Heart (NASDAQ:CHFS) traded down $0.05 during midday trading on Tuesday, reaching $3.62. 129,505 shares of the company were exchanged, compared to its average volume of 628,933. The company has a market cap of $6.60, a price-to-earnings ratio of -0.02 and a beta of 2.25. Sunshine Heart has a 1-year low of $2.87 and a 1-year high of $220.60.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at

About Sunshine Heart

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Get a free copy of the Zacks research report on Sunshine Heart (CHFS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with's FREE daily email newsletter.